New download available! VTE Risks and JAK inhibition https://t.co/TCt4PcySYr https://t.co/wBaEsC3Wry

• https://bit.ly/3Z1FIro

BEAT LUPUS trial results showed that belimumab after RTX reduced dsDNA levels/flaring. Questions remain if this can be a successful combination in lupus nephritis. Dr. Kalunian #RNL2023 @RheumNow https://t.co/XeuybrWigf

"I think rheumatologists are great observers, they just need to try meds." Dr. Furie regarding new medications/indications in rheumatology. #RNL2023 @RheumNow

Awareness increased for this disease , BY Atul Deodhar #RNL2023 ⁦@RheumNow⁩ https://t.co/MSBrYU5Pb4

#RNL2023 @RheumNow Atul Deodhar: Prevalence of AS is increasing! Is it truly more? Or likely better recognized and diagnosed, as well as increased recognition of nr-AxSpa https://t.co/qNwUg5RtaG

Atul Deodhar's "3-4-5" Rule for MRI Sacroiliac Jts (SIJ) Erosion in 3+ SIJ quadrants Bone marrow edema 4+ SIJ quadrants Fat lesion in 5+ SI joint @Rheumnow #RNL2023 https://t.co/AHZUhhEmmC

Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS. *Erosions in 3 or more SIJ quadrants *BME in 4 or more SIJ quadrants *Fat lesions in 5 of more SIJ quadrants #RNL2023 @RheumNow https://t.co/2m8TmkQo0A

Dr. Atul Deodhar on AxSpA - 5-40% of nr-axSpA progress to r-axSpA over 2-10 years - is non-radiographic axSpA a misnomer? @RheumNow #RNL2023 https://t.co/bhwlbg6eWN

Risk factors for radiographic progression: Men ♂️ Smoking 🚬 Active inflammation🔥 Blue collar workers 💪 HLA-B27+ 💉 Pre-existing syndesmophyte 🩻 Atul Deodhar at #RNL2023 @RheumNow https://t.co/9ibHTEhi9k

No significance difference in radiographic progression in patients with IL17-TNF , BY Atul Deodhar #RNL2023 ⁦@RheumNow⁩ https://t.co/S3NQ4mWgjt

SURPASS: SEC vs ADA for axSpA Outcome: %pts with no radiographic progression Not benefit- Secukinumab not better than adalimumab Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! @RheumNow #RNL2023 https://t.co/Vt58jSXCMd

First Head-to-Head bDMARD study in axSpA to assess radiographic progression - secukinumab vs. adalimumab biosimilar - 66% of either arm prevented radiographic progression - no difference between two arms but good news is radiographic progression is low! @RheumNow #RNL2023 https://t.co/xq8GhN7kzr

Late breaking ACR abstract '22 SURPASS study (H2H TNFi vs IL17 in AS radiographic progression.) Primary endpoint was not met. However, Dr. Deodhar's take away: spinal radiographic progression over 2 years is very low despite high disease activity in both txs! #RNL2023 @RheumNow https://t.co/TsukRs29pC

Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS - it works but is it different from existing IL-17i? - appears to work well in TNFi-inadequate responders - are TNFi-IR pts immunologically different? niche category for IL-17A and F use? @RheumNow #RNL2023 https://t.co/dWkakahHAi

Dennis Poddubnyy #RNL2023 MRI sequences for axSpA: Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression Semi-axial- T2 STIR @RheumNow https://t.co/ySk4hU5lMY